Conexeu Sciences raises $1.5M in October 2026 SEC filing

By Find your role first team · October 21, 2026, 23:20 UTC

Conexeu Sciences, a Biotechnology company based in NV, began filing with the SEC in July 2025. Its first reported sale was for $1.3M in April 2025, an estimated Pre-seed/Seed round. Conexeu Sciences has reported 18 funding rounds, all estimated Seed rounds, since April 2025. Rounds are estimates based on available data.

The company's funding amounts have varied. After the initial $1.3M, subsequent raises included $2.9M in October 2025, $1.8M in March 2026, and $1.5M in October 2026. Other rounds were smaller, such as $2K in June 2026 and $1K in May 2026.

The latest filing in October 2026 lists David Bogart (Executive Officer, Director), Miles Harrison (Executive Officer, Director), Aaron Farberg (Director), Stephen Inouye (Executive Officer), Claudia Chavez-Munoz (Executive Officer), Jeff Sharpe (Director), Z Lorenc (Director), and Sebastian Purcell (Director). We do not track its open roles yet.

Every Form D filing

Named in the latest filing

• David BogartExecutive Officer, Director
• Miles HarrisonExecutive Officer, Director
• Aaron FarbergDirector
• Stephen InouyeExecutive Officer
• Claudia Chavez-MunozExecutive Officer
• Jeff SharpeDirector
• Z LorencDirector
• Sebastian PurcellDirector
• Brian PilcherExecutive Officer
• Andrew CostaDirector

From SEC Form D filings. Rounds are our estimate from the amount sold; filings carry no valuation. All filings on SEC EDGAR